相关实验视频
Updated: Jun 7, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
PKN2 是一个依赖于介质细胞样癌细胞状态的基因
Shane T Killarney1, Gabriel Mesa1, Rachel Washart1
1Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.
癌细胞使用一个类似细胞介质的状态 (MLS) 来抵抗药物. 准PKN2激酶会破坏这种状态,提供一种克服癌症抗药性的新策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 癌细胞采用一个类似于介质细胞的转录状态 (MLS) 来生存药物治疗.
- 对于这种抗药性状态,已确定很少有治疗点.
研究的目的:
- 为了识别介质细胞类癌症中的新型治疗漏洞.
- 研究PKN2激酶在促进癌症生长和耐药性方面的作用.
主要方法:
- 在大约800个癌症细胞系中对基因基本性得分的系统分析.
- 生物化学实验和对患者瘤的基因组分析.
- 研究了PKN2-SAV1-TAZ信号通路.
主要成果:
- 确定PKN2是MLS癌症中最重要的治疗点.
- 通过PKN2-SAV1-TAZ通路,PKN2促进了间酶体样癌症的生长.
- 将PKN2抑制与向疗法 (EGFR,KRAS,BRAF) 结合起来,通过消除持久细胞,克服了耐药性.
结论:
- PKN2是Hippo瘤抑制器通路的核心调节者.
- 抑制PKN2是一种潜在的策略,可以在各种癌症中克服MLS驱动的耐药性.
- PKN2-TAZ是一种选择性依赖性,存在于介质细胞类癌症中.
更多相关视频
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
相关概念视频
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
MAPK Signaling Cascades